keyword
MENU ▼
Read by QxMD icon Read
search

Rejection splenectomy

keyword
https://www.readbyqxmd.com/read/27534951/results-of-a-multicenter-prospective-clinical-study-in-japan-for-evaluating-efficacy-and-safety-of-desensitization-protocol-based-on-rituximab-in-abo-incompatible-kidney-transplantation
#1
Kota Takahashi, Kazuhide Saito, Shiro Takahara, Shohei Fuchinoue, Takashi Yagisawa, Atsushi Aikawa, Yoshihiko Watarai, Norio Yoshimura, Kazunari Tanabe, Kunio Morozumi, Motohide Shimazu
BACKGROUND: Deceased organ donations are rare in Japan, with most kidney transplants performed from a limited number of living donors. Researchers have thus developed highly successful ABO-incompatible transplantation procedures, emphasizing preoperative desensitization and postoperative immunosuppression. A recent open-label, single-arm, multicenter clinical study prospectively examined the efficacy and safety of rituximab/mycophenolate mofetil desensitization in ABO-incompatible kidney transplantation without splenectomy...
August 17, 2016: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/27495772/histological-and-extended-clinical-outcomes-following-abo-incompatible-renal-transplantation-without-splenectomy-or-rituximab
#2
Kevin V Chow, Shaun M Flint, Angeline Shen, Anthony Landgren, Moira Finlay, Anand Murugasu, Rosemary Masterson, Peter Hughes, Solomon J Cohney
BACKGROUND: Excellent short-term results have been reported in ABO-incompatible renal transplant recipients (ABOi) managed solely with antibody removal and conventional immunosuppression. However, long-term clinical outcomes with this regimen and predictive information from protocol biopsies is lacking. METHODS: We compared outcome data in ABOi and ABO compatible (ABOc) recipients receiving this regimen approximately 4 years posttransplant, and histology from biopsies approximately 12 month posttransplant...
August 5, 2016: Transplantation
https://www.readbyqxmd.com/read/27374679/successful-long-term-graft-survival-of-a-renal-transplantation-patient-with-wiskott-aldrich-syndrome
#3
Kotaro Kai, Maki Sumida, Yaeko Motoyoshi, Yuichi Ogawa, Katsuyuki Miki, Kazuhiro Iwadoh, Akihito Sannomiya, Toru Murakami, Ichiro Koyama, Kumiko Kitajima, Ichiro Nakajima, Tomohiro Morio, Shohei Fuchinoue
Wiskott-Aldrich syndrome, a rare X-linked hereditary syndrome, is characterized by immunodeficiency, thrombocytopenia, and eczema. The underlying T-cell defect renders renal transplantation and immunosuppressive treatments uncertain. The present case exhibited the mild clinical manifestation, regarded as X-linked thrombocytopenia. He successfully underwent a living-donor ABO-compatible renal transplantation and splenectomy in 2002, and thereafter experiencing no severe rejection, serious infection, or malignancy for more than 10 years...
2016: Internal Medicine
https://www.readbyqxmd.com/read/27320573/single-center-experience-of-abo-incompatible-living-donor-liver-transplantation-with-a-new-simplified-intravenous-immunoglobulin-protocol-a-propensity-score-matching-analysis
#4
J D Kim, D L Choi, S-G Kim, A-J Lee
The outcomes of patients who undergo ABO-incompatible (ABO-I) living-donor liver transplantation (LDLT) have markedly improved as strategies have become more innovative and advanced. Here, we describe 25 cases of ABO-I LDLT with a simplified protocol and compare the outcomes to those of ABO-compatible LDLT. We analyzed outcomes via a retrospective review of 182 adult LDLT cases including 25 ABO-I LDLTs from January 2011 to December 2014. Propensity scoring was used to compare the groups. The desensitization protocol included plasma exchange, rituximab, and intravenous immunoglobulin without local infusion therapy...
May 2016: Transplantation Proceedings
https://www.readbyqxmd.com/read/27231173/individualized-immunosuppressive-protocol-of-liver-transplant-recipient-should-be-made-based-on-splenic-function-status
#5
Ji-Yong Song, Guo-Sheng Du, Li Xiao, Wen Chen, Long-Long Suo, Yu Gao, Li-Kui Feng, Bing-Yi Shi
BACKGROUND: Lymphocyte subsets play important roles in rejection in liver transplant recipients, and the effect of splenic function on these roles remains unknown. The aim of this study was to explore the feasibility to adjust immunosuppressive agents based on splenic function status through detecting the lymphocyte subsets in liver transplantBeijing recipients. METHODS: The lymphocyte subsets of 49 liver transplant recipients were assessed in the 309th Hospital of Chinese People's Liberation Army between June 2014 and August 2015...
June 5, 2016: Chinese Medical Journal
https://www.readbyqxmd.com/read/27214874/splenic-irradiation-for-the-treatment-of-severe-antibody-mediated-rejection
#6
B J Orandi, B E Lonze, A Jackson, S Terezakis, E S Kraus, N Alachkar, S M Bagnasco, D L Segev, J B Orens, R A Montgomery
Patients requiring desensitization prior to renal transplantation are at risk for developing severe antibody-mediated rejection (AMR) refractory to treatment with plasmapheresis and intravenous immunoglobulin (PP/IVIg). We have previously reported success at graft salvage, long-term graft survival and protection against transplant glomerulopathy with the use of eculizumab and splenectomy in addition to PP/IVIg. Splenectomy may be an important component of this combination therapy and is itself associated with a marked reduction in donor-specific antibody (DSA) production...
May 23, 2016: American Journal of Transplantation
https://www.readbyqxmd.com/read/27115002/feasible-usage-of-abo-incompatible-grafts-in-living-donor-liver-transplantation
#7
Toru Ikegami, Tomoharu Yoshizumi, Yuji Soejima, Hideaki Uchiyama, Ken Shirabe, Yoshihiko Maehara
BACKGROUND: The use of ABO incompatible (ABOi) graft in living donor liver transplantation (LDLT) has not been an established procedure worldwide. METHODS: Four hundred and eight adult LDLTs, using ABOi (n=19) and non-ABOi (n=389) grafts, were performed as a single center experience. RESULTS: In ABOi-LDLT group (n=19), median isoagglutinin titer before plasma exchange (PE) at LDLT and after LDLT (max) was ×256, ×32 and ×32, respectively...
April 2016: Hepatobiliary Surgery and Nutrition
https://www.readbyqxmd.com/read/26637210/low-dose-of-mycophenolate-mofetil-is-enough-in-desensitized-kidney-transplantation-using-rituximab
#8
Chung Hee Baek, Hyosang Kim, Hoon Yu, Eunhye Shin, Hyungjin Cho, Won Seok Yang, Duck Jong Han, Su-Kil Park
BACKGROUND: Rituximab is widely used in kidney transplantation. However, it is not clear whether the conventional doses of maintenance immunosuppressant in rituximab-treated kidney transplantation (KT) are appropriate. In our previous study, decreasing mycophenolate mofetil (MMF) dose due to infection did not increase the incidence of rejection or graft failure. Based on these experiences, we developed a new protocol with a lower dose of MMF and studied its clinical outcomes in rituximab-treated KT...
December 4, 2015: BMC Nephrology
https://www.readbyqxmd.com/read/26622429/high-dose-immunosuppressant-alters-the-immunological-status-of-new-zealand-white-rabbits-following-skin-transplantation
#9
Peilun Cheng, Liming Zhong, Zesheng Jiang, Yan Wang, Mingxin Pan, Y I Gao
The aim of this study was to investigate the effect of an immunosuppressant on the immunological status of New Zealand white rabbits after skin grafting, and to evaluate a method for monitoring the immunological status of subjects with skin transplants. The rabbits were randomly divided into allograft rejection, autograft tolerance, nontransplant, allograft low-dose immunosuppressant and allograft high-dose immunosuppressant groups. The rabbits in the low- and high-dose immunosuppressant groups were treated with cyclosporine A intravenously 8 h prior to skin transplantation and once daily following transplantation at doses of 2 and 25 mg/kg, respectively...
September 2015: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/26372830/abo-incompatible-adult-living-donor-liver-transplantation-under-the-desensitization-protocol-with-rituximab
#10
G-W Song, S-G Lee, S Hwang, K-H Kim, C-S Ahn, D-B Moon, T-Y Ha, D-H Jung, G-C Park, W-J Kim, M-H Sin, Y-I Yoon, W-H Kang, S-H Kim, E-Y Tak
ABO incompatibility is no longer considered a contraindication for adult living donor liver transplantation (ALDLT) due to various strategies to overcome the ABO blood group barrier. We report the largest single-center experience of ABO-incompatible (ABOi) ALDLT in 235 adult patients. The desensitization protocol included a single dose of rituximab and total plasma exchange. In addition, local graft infusion therapy, cyclophosphamide, or splenectomy was used for a certain time period, but these treatments were eventually discontinued due to adverse events...
January 2016: American Journal of Transplantation
https://www.readbyqxmd.com/read/26108258/evaluation-of-blood-group-antibodies-in-abo-incompatible-living-donor-kidney-transplantation
#11
Ken Sugiyama, Yoji Hyodo, Atsushi Aikawa
OBJECTIVE: To assess changes in anti-blood type antibody titers and postoperative outcomes (graft survival and rejection rates) at our center with the use of the immunosuppressant, rituximab, in ABO-incompatible kidney transplants from living donors. Confirming anti-donor blood group antibodies is important for avoiding humoral rejection in ABO-incompatible kidney transplants. Splenectomy has been carried out in our hospital according to Alexandre's policy in order to suppress the production of anti-donor blood group antibodies...
October 2015: International Journal of Urology: Official Journal of the Japanese Urological Association
https://www.readbyqxmd.com/read/25891718/results-of-abo-incompatible-liver-transplantation-using-a-simplified-protocol-at-a-single-institution
#12
J Lee, J G Lee, J J Lee, M S Kim, M K Ju, G H Choi, J S Choi, S I Kim, D J Joo
BACKGROUND: Because of the development of various desensitization strategies, ABO-incompatible (ABOi) living donor liver transplantation (LDLT) has become a feasible option for patients with end-stage liver disease. However, there has been no united desensitization protocol for ABOi LDLT. We analyzed the outcomes after establishment of simplified protocol without splenectomy, intravenous immunoglobulin, and local infusion therapy. METHODS: We analyzed 19 ABOi LDLT cases that had been performed between January 2012 and December 2013, without splenectomy and local infusion...
April 2015: Transplantation Proceedings
https://www.readbyqxmd.com/read/25808777/successful-abo-incompatible-living-related-intestinal-transplantation-a-2-year-follow-up
#13
D M Fan, Q C Zhao, W Z Wang, H Shi, M Wang, D L Chen, J Y Zheng, M B Li, G S Wu
ABO-incompatible intestinal transplantation has rarely been performed due to poor patient outcomes. Herein we present a case of successful ABO-incompatible intestinal transplantation with a 2-year follow-up. A 16-year-old female with a history of extensive bowel resection received an ABO-incompatible living donor bowel graft from her father (blood type AB graft into a type A recipient). Posttransplant immunosuppression consisted of an initial anti-CD20, plasmapheresis/intravenous immunoglobulin before transplantation, followed by an anti-thymocyte globulin (ATG) induction and splenectomy, and maintenance with tacrolimus and prednisone...
May 2015: American Journal of Transplantation
https://www.readbyqxmd.com/read/25449537/kinetics-of-b-t-nk-lymphocytes-and-isoagglutinin-titers-in-abo-incompatible-living-donor-liver-transplantation-using-rituximab-and-basiliximab
#14
Seung Duk Lee, Seong Hoon Kim, Sun-Young Kong, Young-Kyu Kim, Sang-Jae Park
BACKGROUND: The kinetics of isoagglutinin titers and lymphocyte subpopulations including B, T, and natural killer (NK) cells after ABO incompatible (ABO-I) living donor liver transplantation (LDLT) have not been evaluated. METHODS: From January 2012 to July 2013, consecutive ABO-I LDLT patients were enrolled at the National Cancer Center. Our desensitizing protocol included rituximab, plasma exchanges, basiliximab, and intravenous immune globulin without splenectomy...
January 2015: Transplant Immunology
https://www.readbyqxmd.com/read/25389083/abo-incompatible-renal-transplantation-without-antibody-removal-using-conventional-immunosuppression-alone
#15
COMPARATIVE STUDY
R Masterson, P Hughes, R G Walker, C Hogan, M Haeusler, A R Robertson, R Millar, N Suh, S J Cohney
ABO incompatible living donor renal transplantation (ABOi) can achieve outcomes comparable to ABO compatible transplantation (ABOc). However, with the exception of blood group A2 kidneys transplanted into recipients with low titer anti-A antibody, regimens generally include antibody removal, intensified immunosuppression and splenectomy or rituximab. We now report a series of 20 successful renal transplants across a range of blood group incompatibilities using conventional immunosuppression alone in recipients with low baseline anti-blood group antibody (ABGAb) titers...
December 2014: American Journal of Transplantation
https://www.readbyqxmd.com/read/25387763/an-update-on-abo-incompatible-kidney-transplantation
#16
REVIEW
Stefan Zschiedrich, Albrecht Kramer-Zucker, Bernd Jänigen, Maximilian Seidl, Florian Emmerich, Przemyslaw Pisarski, Tobias B Huber
ABO-incompatible kidney transplantation is nowadays a well-established procedure to expand living donor transplantation to blood group incompatible donor/recipient constellations. In the last two decades, transplantation protocols evolved to more specific isohaemagglutinin elimination techniques and established competent antirejection protection protocols without the need of splenectomy. ABOi kidney transplantation associated accommodation despite isohaemagglutinin reappearance, C4d positivity of peritubular capillaries as well as the increased incidence of bleeding complications is currently under intense investigation...
April 2015: Transplant International: Official Journal of the European Society for Organ Transplantation
https://www.readbyqxmd.com/read/25248763/splenectomy-promotes-indirect-elimination-of-intraocular-tumors-by-cd8-t-cells-that-is-associated-with-ifn%C3%AE-and-fas-fasl-dependent-activation-of-intratumoral-macrophages
#17
Maxine R Miller, Jonathan B Mandell, Kelly M Beatty, Stephen A K Harvey, Michael J Rizzo, Dana M Previte, Stephen H Thorne, Kyle C McKenna
Ocular immune privilege (IP) limits the immune surveillance of intraocular tumors as certain immunogenic tumor cell lines (P815, E.G7-OVA) that are rejected when transplanted in the skin grow progressively when placed in the anterior chamber of the eye. As splenectomy (SPLNX) is known to terminate ocular IP, we characterized the immune mechanisms responsible for rejection of intraocular tumors in SPLNX mice as a first step toward identifying how to restore tumoricidal activity within the eye. CD8(+) T cells, IFNγ, and FasL, but not perforin, or TNFα were required for the elimination of intraocular E...
December 2014: Cancer Immunology Research
https://www.readbyqxmd.com/read/25124898/-analysis-of-the-curative-effect-of-abo-incompatible-liver-transplantation-in-the-treatment-in-patients-with-acute-severe-liver-disease
#18
Zhongyang Shen, Yonglin Deng, Hong Zheng, Cheng Pan, Yamin Zhang, Wentao Jiang, Jianjun Zhang, Wei Gao, Mingsheng Huai, Rui Shi
OBJECTIVE: To analyze and evaluate the clinical effect of ABO-incompatible liver transplantation in the treatment of acute severe liver disease. METHODS: A retrospective clinical study was conducted. The clinical data of 4 136 patients undergoing orthotopic liver transplantation in Organ Transplantation Center of Tianjin First Center Hospital from September 1999 to December 2013 were analyzed. The criteria of patients enrolled were as following: model for end-stage liver disease (MELD) score ≥ 20, the donor's and recipient's blood types were different, age 18-70 years, and undergone primary non-bypass orthotopic liver transplantation...
August 2014: Zhonghua Wei Zhong Bing Ji Jiu Yi Xue
https://www.readbyqxmd.com/read/25121475/eculizumab-and-splenectomy-as-salvage-therapy-for-severe-antibody-mediated-rejection-after-hla-incompatible-kidney-transplantation
#19
Babak J Orandi, Andrea A Zachary, Nabil N Dagher, Serena M Bagnasco, Jacqueline M Garonzik-Wang, Kyle J Van Arendonk, Natasha Gupta, Bonnie E Lonze, Nada Alachkar, Edward S Kraus, Niraj M Desai, Jayme E Locke, Lorraine C Racusen, Dorry L Segev, Robert A Montgomery
BACKGROUND: Incompatible live donor kidney transplantation is associated with an increased rate of antibody-mediated rejection (AMR) and subsequent transplant glomerulopathy. For patients with severe, oliguric AMR, graft loss is inevitable without timely intervention. METHODS: We reviewed our experience rescuing kidney allografts with this severe AMR phenotype by using splenectomy alone (n=14), eculizumab alone (n=5), or splenectomy plus eculizumab (n=5), in addition to plasmapheresis...
October 27, 2014: Transplantation
https://www.readbyqxmd.com/read/25100124/a-modified-protocol-with-rituximab-and-intravenous-immunoglobulin-in-emergent-abo-incompatible-liver-transplantation-for-acute-liver-failure
#20
Tian Shen, Bing-Yi Lin, Jun-Jun Jia, Zhuo-Yi Wang, Li Wang, Qi Ling, Lei Geng, Sheng Yan, Shu-Sen Zheng
BACKGROUND: The established procedure for ABO-incompatible liver transplantation (ABO-I LT) was too complicated to be used in case of emergency. We developed a protocol consisting of rituximab and intravenous immunoglobulin (IVIG) for ABO-I LT in patients with acute liver failure (ALF). METHODS: The data from 101 patients who had undergone liver transplantation (LT) for ALF were retrospectively analyzed. The patients were divided into two groups: ABO-compatible liver transplantation group (ABO-C LT, n=66) and ABO-I LT group (n=35)...
August 2014: Hepatobiliary & Pancreatic Diseases International: HBPD INT
keyword
keyword
35097
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"